COVID-19: FDA Eases Approval Policy By Allowing LDT Use Under ‘Immediately In Effect’ Guidance

The US FDA on 29 February issued a new guidance giving the OK to labs with pending COVID-19 laboratory-developed tests (LDTs) to use them while they await the agency’s approval under Emergency Use Authorization. The agency issued the guidance quickly, taking the unusual step of forgoing a public comment period.

Nurse wearing respirator mask holding a positive blood test result for the new rapidly spreading Coronavirus, originating in Wuhan, China

The US Food and Drug Administration issued a new guidance on 29 February giving the OK to labs with pending COVID-19 laboratory-developed tests (LDTs) to use them while they await the agency’s approval under its Emergency Use Authorization (EUA).

The agency’s new coronavirus test policy – in the form of Immediately in Effect FDA Guidance for Clinical Labs...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation